Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$42.72
-2.0%
$46.01
$17.86
$58.40
$3.40B-0.19819,115 shs594,217 shs
Genmab A/S stock logo
GMAB
Genmab A/S
$19.90
-1.2%
$20.89
$18.64
$30.50
$13.17B0.98957,826 shs1.11 million shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.81
+0.0%
$129.12
$64.09
$131.87
$14.04B0.691.39 million shs1.58 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$31.12
-3.1%
$34.72
$29.25
$170.47
$12.03B1.866.82 million shs5.68 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%-5.53%-13.03%+52.79%+69.12%
Genmab A/S stock logo
GMAB
Genmab A/S
0.00%+0.71%-12.21%-4.19%-33.47%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%+0.12%+2.82%+57.89%+90.48%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-4.72%+0.52%-20.98%-70.80%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
4.328 of 5 stars
4.51.00.04.73.61.70.0
Genmab A/S stock logo
GMAB
Genmab A/S
3.9295 of 5 stars
4.43.00.00.02.00.03.1
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
3.5843 of 5 stars
2.23.00.04.52.91.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.0995 of 5 stars
4.01.00.04.61.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$76.2978.57% Upside
Genmab A/S stock logo
GMAB
Genmab A/S
2.77
Moderate Buy$41.33107.71% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.47
Hold$106.08-19.52% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.0089.59% Upside

Current Analyst Ratings Breakdown

Latest AKRO, ITCI, MRNA, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/11/2025
Genmab A/S stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $45.00
3/11/2025
Genmab A/S stock logo
GMAB
Genmab A/S
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/3/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$72.00 ➝ $75.00
3/2/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
2/24/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$140.00 ➝ $132.00
2/21/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$9.61 per shareN/A
Genmab A/S stock logo
GMAB
Genmab A/S
$21.53B0.61$1.34 per share14.80$8.04 per share2.48
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.63N/AN/A$6.15 per share21.43
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.76N/AN/A$28.33 per share1.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$151.76M-$3.75N/AN/AN/AN/A-32.46%-29.83%5/9/2025 (Estimated)
Genmab A/S stock logo
GMAB
Genmab A/S
$1.14B$1.7411.4411.182.6536.30%16.78%13.79%5/1/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A693.74N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)

Latest AKRO, ITCI, MRNA, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/28/2025Q4 2024
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$0.98-$0.99-$0.01-$0.99N/AN/A
2/21/2025Q4 2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million
2/12/2025Q4 2024
Genmab A/S stock logo
GMAB
Genmab A/S
$0.28$0.57+$0.29$0.85$884.02 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.05
17.25
17.25
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
5.25
5.24
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.94%
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.62 million64.26 millionOptionable
Genmab A/S stock logo
GMAB
Genmab A/S
1,660661.77 million651.58 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable

Recent News About These Companies

Moderna brand chief Kate Cronin leaves for 'next chapter'
Citi Keeps Their Hold Rating on Moderna (MRNA)
The anti-vax culture war on mRNA just got worse

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$42.72 -0.86 (-1.97%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$42.70 -0.02 (-0.04%)
As of 03/28/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$19.90 -0.24 (-1.19%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$19.90 +0.01 (+0.03%)
As of 03/28/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.81 +0.06 (+0.05%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$131.84 +0.03 (+0.03%)
As of 03/28/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$31.12 -1.00 (-3.11%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$31.22 +0.11 (+0.34%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.